Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 9, 2007, Pages 1092-1099

  Nguyen, Geoffrey C ^a   Segev, Dorry L ^a   Thuluvath, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFIDENCE INTERVAL; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORTALITY; PORTAL HYPERTENSION; RETROSPECTIVE STUDY; RISK; UNITED STATES;

CONFIDENCE INTERVALS; FEMALE; HEPATITIS C; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPERTENSION, PORTAL; INCIDENCE; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 35748983225     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.04.027     Document Type: Article

References (32)

1. Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54:1-49.
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
3. Talwalkar JA, Kamath PS. Influence of recent advances in medical management on clinical outcomes of cirrhosis. Mayo Clin Proc 2005;80:1501-1508.
4. Shiffman ML, Saab S, Feng S, et al. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-1187.
5. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
6. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.
7. Kim WR, Gross JB Jr, Poterucha JJ, et al. Outcome of hospitalcare of liver disease associated with hepatitis C in the United States. Hepatology 2001;33:201-206.
8. Whalen D, Houchens R, Elixhauser A. 2002 HCUP nationwide inpatient sample (NIS) comparison report. # 2005-03 ed. Rockville, Maryland US Agency for Healthcare Research and Quality, 2005:1-89.
9. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991;100:1619-1636.
10. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006;24:661-672.
11. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-S10.
12. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004;4:686-693.
13. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-539.
14. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83.
15. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
16. Ong JP, Collantes R, Pitts A, et al. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol 2005;39:826- 830.
17. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31: 777-782.
18. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S34.
19. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-1137.
20. Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-1338.
21. Hornberger J, Farci P, Prati D, et al. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006;13:377-386.
22. Markowitz JS, Gutterman EM, Hodes D, et al. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. J Viral Hepat 2005;12:176- 185.
23. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-389.
24. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809.
25. Maddrey WC. Alcohol-induced liver disease. Clin Liver Dis 2000; 4:115-131, vii.
26. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213.
27. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004;24:217-232.
28. Hermos JA. Drinking by alcoholic cirrhotic patients under medical care: a literature survey. Alcohol Clin Exp Res 1984;8:314-318.
29. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
30. Sloan KL, Straits-Troster KA, Dominitz JA, et al. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol 2004;38:279-284.
31. Mansell D, Penk W, Hankin CS, et al. The illness burden of alcohol-related disorders among VA patients: the veterans health study. J Ambul Care Manage 2006;29:61-70.
32. Kulkarni S, Cronin DC. Ethics in liver transplantation. Semin Liver Dis 2006;26:234-238.